［1］ Ovarian cancer, five-year stage-specific relative survival rates (2004-2008). Journal of the National Cancer Institute, 2011，103:1287.

［2］ Powell DE, Puls L, van Nagell J. Current concepts in epithelial ovarian tumors: does benign to malignant transformation occur?［J］. Human Pathology, 1992，23:846-847.

［3］ Puls LE, Powell DE, DePriest PD,et al. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma［J］. Gynecol Oncol，1992，47:53-57.

［4］ Dubeau L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes?［J］. Gynecol Oncol, 1999,72:437-442.

［5］ Singer G, Kurman RJ, Chang HW, et al. Diverse tumorigenic pathways in ovarian serous carcinoma［J］. The American Journal of Pathology, 2002,160:1223-1228.

［6］ Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis［J］. The American Journal of Pathology, 2004,164:1511-1518.

［7］ Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system［J］. The American Journal of Surgical Pathology, 2004,28:496-504.

［8］ Cho KR, Shih IM. Ovarian cancer［J］. Annual Review of Pathology, 2009,4:287-313.

［9］ Kurman RJ, Shih IM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. International journal of gynecological pathology : official journal of the international［J］. Society of Gynecological Pathologists, 2008,27:151-160.

［10］ Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma［J］. Nature, 2011,474:609-615.

［11］ Kindelberger DW, Lee Y, Miron A,et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship［J］. The American Journal of Surgical Pathology, 2007,31:161-169.

［12］ Lee Y, Miron A, Drapkin R,et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube［J］. The Journal of Pathology, 2007,211:26-35.

［13］ Pothuri B, Leitao MM, Levine DA, et al. Genetic analysis of the early natural history of epithelial ovarian carcinoma［J］. PloS One, 2010,5:e10358.

［14］ Dehari R, Kurman RJ, Logani S,et al. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis［J］. The American Journal of Surgical Pathology, 2007,31:1007-1012.

［15］ Vang R, Shih Ie M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems［J］. Advances in Anatomic Pathology, 2009,16:267-282.

［16］ May T, Virtanen C, Sharma M,et al. Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary［J］. Gynecol Oncol,2010,117:9-17.

［17］ Seidman JD, Kurman RJ. Treatment of micropapillary serous ovarian carcinoma (the aggressive variant of serous borderline tumors)［J］. Cancer, 2002,95:675-676.

［18］ Li J, Abushahin N, Pang S,et al. Tubal origin of 'ovarian' low-grade serous carcinoma［M］. Modern Pathology:An Official journal of the United States and Canadian Academy of Pathology,2011:1488-1499.

［19］ Partridge E, Kreimer AR, Greenlee RT, et al. Results from four rounds of ovarian cancer screening in a randomized trial［J］. Obstet Gynecol, 2009,113:775-782.

［20］ Buys SS, Partridge E, Greene MH, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial［J］. Am J of Obstetrics and Gynecology, 2005,193:1630-1639.

［21］ Santillan A, Kim YW, Zahurak ML,et al. Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma: international journal of gynecological cancer : official journal of the international［J］. Gynecological Cancer Society, 2007,17:601-606.